Erythropoiesis-Stimulating Agent (ESA)

DRUG3 trials

Sponsors

Vifor Fresenius Medical Care Renal Pharma, Akebia Therapeutics, Bristol-Myers Squibb

Conditions

AnemiaAnemia of Chronic Kidney DiseaseEnd Stage Renal DiseaseMyelodysplastic Syndromes (MDS)

Phase 3

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Active, not recruitingNCT06901505

Akebia TherapeuticsAnemia of Chronic Kidney Disease

Start: 2025-07-24End: 2026-08-01Updated: 2026-02-23

Unknown Phase

Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial

TerminatedNCT03214627

Vifor Fresenius Medical Care Renal PharmaAnemia, End Stage Renal Disease

Start: 2018-12-10End: 2019-05-21Updated: 2020-01-07

A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept

Active, not recruitingNCT06971185

Bristol-Myers SquibbMyelodysplastic Syndromes (MDS)

Start: 2024-11-22End: 2025-08-01Target: 430Updated: 2025-05-14